Clinical Significance
CD20 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias.
The anti-CD20 mAB Ofatumumab (Genmab) was approved by FDA in Oct 2009 for Chronic lymphocytic leukemia.
Additional anti-CD20 antibody therapeutics under development (phase II or III clinical trials in 2008) include :
- AME-133v (by Applied Molecular Evolution),
- Ocrelizumab for multiple sclerosis (rheumatoid arthritis discontinued in 2010),
- TRU-015 (by Trubion), (discontinued in 2010)
- IMMU-106 (veltuzumab).
Read more about this topic: CD20
Famous quotes containing the word significance:
“Of what significance the light of day, if it is not the reflection of an inward dawn?—to what purpose is the veil of night withdrawn, if the morning reveals nothing to the soul? It is merely garish and glaring.”
—Henry David Thoreau (1817–1862)